HK1250176A1 - 用於确定细胞疗法的临床反应的生物标志物 - Google Patents

用於确定细胞疗法的临床反应的生物标志物 Download PDF

Info

Publication number
HK1250176A1
HK1250176A1 HK18109614.7A HK18109614A HK1250176A1 HK 1250176 A1 HK1250176 A1 HK 1250176A1 HK 18109614 A HK18109614 A HK 18109614A HK 1250176 A1 HK1250176 A1 HK 1250176A1
Authority
HK
Hong Kong
Prior art keywords
clinical response
biomarkers
determining
cell therapy
mscs
Prior art date
Application number
HK18109614.7A
Other languages
English (en)
Chinese (zh)
Inventor
Olga De La Rosa
Wilfried Dalemans
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HK1250176A1 publication Critical patent/HK1250176A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7156—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
HK18109614.7A 2015-04-24 2016-04-25 用於确定细胞疗法的临床反应的生物标志物 HK1250176A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15382206 2015-04-24
EP15382206.9 2015-04-24
PCT/EP2016/059196 WO2016170187A2 (en) 2015-04-24 2016-04-25 Biomarkers for determining the clinical response to cell therapy

Publications (1)

Publication Number Publication Date
HK1250176A1 true HK1250176A1 (zh) 2018-11-30

Family

ID=53015749

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109614.7A HK1250176A1 (zh) 2015-04-24 2016-04-25 用於确定细胞疗法的临床反应的生物标志物

Country Status (7)

Country Link
US (1) US10746729B2 (enExample)
EP (1) EP3286562B1 (enExample)
JP (1) JP6811724B2 (enExample)
CA (1) CA2983950A1 (enExample)
HK (1) HK1250176A1 (enExample)
IL (1) IL255243B (enExample)
WO (1) WO2016170187A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7343091B2 (ja) * 2018-06-05 2023-09-12 メディポスト・カンパニー・リミテッド 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物
WO2020009648A1 (en) * 2018-07-02 2020-01-09 Nextcell Pharma Ab Msc prediction algorithm
CN113544261B (zh) * 2019-02-27 2024-10-01 武田药品工业株式会社 用于同种异体疗法的改良的干细胞群

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298861B1 (en) * 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP5539886B2 (ja) * 2007-10-17 2014-07-02 ティクセル Ｔｒ１細胞、間葉系幹細胞およびその使用
US20140219921A1 (en) * 2012-12-21 2014-08-07 Rutgers, The State University Of New Jersey Immunomodulating compositions and methods
AU2014230014B2 (en) * 2013-03-15 2019-11-14 Tigenix, S.A.U. Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(MSC)
JP6412933B2 (ja) * 2013-06-25 2018-10-24 ティジェニクス エス．エー．ユー． 免疫調節活性を有する細胞集団、その調製方法および使用

Also Published As

Publication number Publication date
IL255243B (en) 2021-04-29
US10746729B2 (en) 2020-08-18
CA2983950A1 (en) 2016-10-27
JP2018513388A (ja) 2018-05-24
EP3286562A2 (en) 2018-02-28
WO2016170187A3 (en) 2016-12-01
US20180156785A1 (en) 2018-06-07
EP3286562B1 (en) 2020-08-12
WO2016170187A2 (en) 2016-10-27
JP6811724B2 (ja) 2021-01-13
IL255243A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
WO2014004990A3 (en) Methods for determining drug efficacy using cereblon-associated proteins
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
TN2013000412A1 (en) Bcma-based stratification and therapy for multiple myeloma patients
DK3083997T3 (da) Diagnostiske, prognostiske og terapeutiske anvendelser af lange ikke-kodende rna¿er til hjertelidelser og regenerativ lægemiddel
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
CA2878044C (en) Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
MX350010B (es) Inhibidores syk de imidazopiridinas.
GB201309758D0 (en) Generation of neural stem cells from human trophoblast stem cells
MX387333B (es) Inhibidores de glucosilceramida sintasa.
UA115540C2 (uk) Антитіло до il-36r
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201590359A1 (ru) Лечение ревматоидного артрита
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
HK1197085A1 (en) Genetic variants for predicting risk of breast cancer
HK1250176A1 (zh) 用於确定细胞疗法的临床反应的生物标志物
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
WO2015069883A8 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab
WO2014169011A3 (en) Methods for treating immune diseases
MX371426B (es) Metodo para la prediccion de la aparicion de sintomas extrapiramidales (sep) inducidos por un tratamiento con antipsicoticos.
WO2013188823A3 (en) Cancer prognostic assays
EP4289970A3 (en) Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
MD805Y (ro) Metodă de diagnostic diferenţial al formelor de amigdalită cronică de etiologie streptococică la copii